Weekly Investment Analysts’ Ratings Changes for Teleflex (TFX)

Teleflex (NYSE: TFX) recently received a number of ratings updates from brokerages and research firms:

  • 9/19/2017 – Teleflex was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Teleflex Inc. designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company offers its products to hospitals and healthcare providers through its direct sales force and distributors. Teleflex was founded in 1943 and is headquartered in Wayne, Pennsylvania. “
  • 9/18/2017 – Teleflex had its “buy” rating reaffirmed by analysts at Deutsche Bank AG. They now have a $251.00 price target on the stock, up previously from $238.00.
  • 9/12/2017 – Teleflex had its “overweight” rating reaffirmed by analysts at Barclays PLC. They now have a $253.00 price target on the stock, up previously from $230.00. They wrote, “XLRS Progressing Slowly with Some Uncertainty. Although top-line safety data from 12 patients in the Phase I/II XLRS dose escalation study did not reveal SAEs and moderate ocular inflammation was considered manageable, the combination of inter-patient and test variability has affected the ability to determine a therapeutic effect. As a result, AGTC plans to expand enrollment and follow the new patients for at least six months.””
  • 9/12/2017 – Teleflex was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $261.00 price target on the stock. According to Zacks, “Teleflex Inc. designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company offers its products to hospitals and healthcare providers through its direct sales force and distributors. Teleflex was founded in 1943 and is headquartered in Wayne, Pennsylvania. “
  • 9/9/2017 – Teleflex was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Teleflex Inc. designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company offers its products to hospitals and healthcare providers through its direct sales force and distributors. Teleflex was founded in 1943 and is headquartered in Wayne, Pennsylvania. “
  • 9/8/2017 – Teleflex had its price target raised by analysts at Jefferies Group LLC from $253.00 to $270.00. They now have a “buy” rating on the stock.
  • 9/7/2017 – Teleflex was upgraded by analysts at Leerink Swann from a “market perform” rating to an “outperform” rating. They now have a $266.00 price target on the stock, up previously from $227.00.
  • 9/6/2017 – Teleflex had its “hold” rating reaffirmed by analysts at KeyCorp.
  • 9/6/2017 – Teleflex was upgraded by analysts at Morgan Stanley from an “equal weight” rating to an “overweight” rating. They now have a $274.00 price target on the stock, up previously from $220.00.
  • 9/5/2017 – Teleflex had its price target raised by analysts at Needham & Company LLC from $228.00 to $237.00. They now have a “buy” rating on the stock. They wrote, “TFX announced it is acquiring NeoTract for $725M of cash upfront and up to another $375M of revenue-based milestone payments. NeoTract has an innovative treatment for benign prostatic hyperplasia (BPH) called UroLift which offers a number of advantages to competing BPH procedures. The BPH market is large and underpenetrated with potential to reach $30B+ worldwide. TFX expects the deal to be accretive to its revenue growth, margins, and EPS by 2019.””
  • 9/1/2017 – Teleflex was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $232.00 price target on the stock. According to Zacks, “Teleflex Inc. designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company offers its products to hospitals and healthcare providers through its direct sales force and distributors. Teleflex was founded in 1943 and is headquartered in Wayne, Pennsylvania. “
  • 8/31/2017 – Teleflex was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Teleflex Inc. designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company offers its products to hospitals and healthcare providers through its direct sales force and distributors. Teleflex was founded in 1943 and is headquartered in Wayne, Pennsylvania. “
  • 8/25/2017 – Teleflex was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $233.00 price target on the stock. According to Zacks, “Teleflex Inc. designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company offers its products to hospitals and healthcare providers through its direct sales force and distributors. Teleflex was founded in 1943 and is headquartered in Wayne, Pennsylvania. “
  • 8/24/2017 – Teleflex was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Teleflex Inc. designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company offers its products to hospitals and healthcare providers through its direct sales force and distributors. Teleflex was founded in 1943 and is headquartered in Wayne, Pennsylvania. “
  • 8/9/2017 – Teleflex had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $253.00 price target on the stock, up previously from $230.00.
  • 8/9/2017 – Teleflex had its “buy” rating reaffirmed by analysts at Deutsche Bank AG. They now have a $238.00 price target on the stock, up previously from $220.00.
  • 8/8/2017 – Teleflex was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 8/4/2017 – Teleflex had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They wrote, “TFX’s 2Q17 revenue and EPS beat consensus. Management maintained its 2017 constant currency revenue growth guidance and raised its adjusted EPS guidance. TFX’s organic revenue growth slowed somewhat to 3.5% in 2Q17 from 4.2% in 1Q17 though we note it faced a more difficult comp. Vascular Solutions’ growth slowed to 11.5% (adjusted for selling days) in 2Q17 from 13.0% in 1Q17. TFX had mixed margin performance with its gross margin up 90 bps Y/Y but its operating margin flat Y/Y.””
  • 8/3/2017 – Teleflex had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $230.00 price target on the stock.
  • 7/31/2017 – Teleflex was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.

Shares of Teleflex Incorporated (TFX) opened at 239.75 on Wednesday. Teleflex Incorporated has a 52 week low of $136.53 and a 52 week high of $240.93. The company has a 50-day moving average price of $216.57 and a 200 day moving average price of $205.08. The stock has a market capitalization of $10.80 billion, a P/E ratio of 45.85 and a beta of 1.05.

Teleflex (NYSE:TFX) last posted its earnings results on Thursday, August 3rd. The medical technology company reported $2.04 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.91 by $0.13. The firm had revenue of $528.60 million for the quarter, compared to analyst estimates of $518.98 million. Teleflex had a return on equity of 16.12% and a net margin of 12.36%. The company’s revenue for the quarter was up 11.6% on a year-over-year basis. During the same period in the previous year, the company posted $1.89 earnings per share. Analysts forecast that Teleflex Incorporated will post $8.28 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Friday, September 15th. Shareholders of record on Tuesday, August 15th were issued a dividend of $0.34 per share. The ex-dividend date was Friday, August 11th. This represents a $1.36 annualized dividend and a yield of 0.57%. Teleflex’s dividend payout ratio is presently 26.00%.

In other Teleflex news, Director Stephen K. M.D. Klasko sold 200 shares of Teleflex stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $211.75, for a total transaction of $42,350.00. Following the transaction, the director now directly owns 8,080 shares in the company, valued at $1,710,940. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Over the last quarter, insiders have sold 600 shares of company stock worth $125,652. Corporate insiders own 2.39% of the company’s stock.

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).

Receive News & Ratings for Teleflex Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply